Skip to content
Try Mental Wellness – Lifestyle
Author:
Mediar Therapeutics
Mediar Therapeutics Announces First Cohorts Dosed in Phase 1 Clinical Trial of MTX-439 for Fibrosis Associated with Chronic Kidney Disease (CKD) and Additions to Clinical Advisory Board
June 23, 2026